The pan-cancer NGS panel selected should, at a minimum, cover all actionable genomic biomarkers in NSCLC as recommended by Cancer Care Ontario [5], as well as other relevant biomarkers that may inform management decisions (e.g., TP53 alterations) and relevant genomic biomarkers for other tumour sites (e.g., ESR1 and AKT pathway genes for breast cancer). The gene discussed is TP53; the disease is non-small cell lung carcinoma.